- Home
- MEIP vs SISI Comparison
MEIP vs SISI Comparison
Compare MEIP & SISI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MEIP
- SISI
- Stock Information
- Founded
- MEIP 2000
- SISI 1997
- Country
- MEIP United States
- SISI China
- Employees
- MEIP N/A
- SISI N/A
- Industry
- MEIP Biotechnology: Pharmaceutical Preparations
- SISI Medicinal Chemicals and Botanical Products
- Sector
- MEIP Health Care
- SISI Health Care
- Exchange
- MEIP Nasdaq
- SISI Nasdaq
- Market Cap
- MEIP 13.3M
- SISI 14.9M
- IPO Year
- MEIP 2003
- SISI 2016
- Fundamental
- Price
- MEIP $2.80
- SISI $0.21
- Analyst Decision
- MEIP Hold
- SISI
- Analyst Count
- MEIP 1
- SISI 0
- Target Price
- MEIP N/A
- SISI N/A
- AVG Volume (30 Days)
- MEIP 13.3K
- SISI 5.5M
- Earning Date
- MEIP 05-13-2025
- SISI 05-15-2025
- Dividend Yield
- MEIP N/A
- SISI N/A
- EPS Growth
- MEIP N/A
- SISI N/A
- EPS
- MEIP N/A
- SISI N/A
- Revenue
- MEIP N/A
- SISI $9,601,324.00
- Revenue This Year
- MEIP N/A
- SISI N/A
- Revenue Next Year
- MEIP N/A
- SISI N/A
- P/E Ratio
- MEIP N/A
- SISI N/A
- Revenue Growth
- MEIP 33.76
- SISI 1133.26
- 52 Week Low
- MEIP $1.46
- SISI $0.18
- 52 Week High
- MEIP $4.10
- SISI $117.65
- Technical
- Relative Strength Index (RSI)
- MEIP 78.43
- SISI 29.00
- Support Level
- MEIP $2.21
- SISI $0.18
- Resistance Level
- MEIP $2.95
- SISI $0.34
- Average True Range (ATR)
- MEIP 0.15
- SISI 0.05
- MACD
- MEIP 0.05
- SISI -0.01
- Stochastic Oscillator
- MEIP 81.48
- SISI 11.25
About MEIP MEI Pharma Inc.
MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States.
About SISI Shineco Inc.
Shineco Inc aims to care for a healthy life and improve the quality of life by providing safe, efficient, and high-quality health products and services to society. The company has researched and developed various vitro diagnostic reagents and related medical devices to date, and it also produces and sells healthy and nutritious food.